Use of botulinum toxin in Parkinson's disease

Angeline Jocson; Mark Lew

doi:10.1016/j.parkreldis.2018.12.002

Use of botulinum toxin in Parkinson's disease

Parkinsonism Relat Disord. 2019 Feb:59:57-64. doi: 10.1016/j.parkreldis.2018.12.002. Epub 2018 Dec 11.

Authors

Angeline Jocson¹, Mark Lew²

Affiliations

¹ Division of Movement Disorders, Department of Neurology, Keck/University of Southern California School of Medicine, Los Angeles, CA, USA. Electronic address: [email protected].
² Division of Movement Disorders, Department of Neurology, Keck/University of Southern California School of Medicine, Los Angeles, CA, USA.

PMID: 30579818
DOI: 10.1016/j.parkreldis.2018.12.002

Abstract

Botulinum toxin has emerged as an important therapeutic intervention within the realm of movement disorders, especially for focal and generalized dystonias. Botulinum toxin has additionally been used for a variety of symptoms associated with parkinsonism. In this review, we will specifically evaluate use of botulinum toxin in idiopathic Parkinson's disease. We will discuss symptoms including sialorrhea, limb, dystonia, tremor, dyskinesias, freezing of gait, camptocormia, pisa syndrome, urinary dysfunction, constipation, dysphagia, eyelid opening apraxia, and blepharospasm.

Keywords: Botulinum toxin; Parkinson's disease.

Publication types

Review

MeSH terms

Acetylcholine Release Inhibitors / pharmacology*
Botulinum Toxins / pharmacology*
Humans
Parkinson Disease / complications*
Parkinson Disease / drug therapy*

Substances

Acetylcholine Release Inhibitors
Botulinum Toxins